BioVector? GLC-82 人肺腺癌細胞株

BioVector? GLC-82 Human Lung Adenocarcinoma Cell Line

第一部分 中文說明

一 產(chǎn)品基本信息與遺傳學(xué)背景

• 細胞名稱 BioVector? GLC-82 人肺腺癌細胞

• 保藏機構(gòu)貨號 國內(nèi)常規(guī)建株株，來源于臨床樣本建立。

• 物種來源 人類 Homo sapiens

• 組織與疾病背景 該細胞株源自一名中國肺腺癌患者的手術(shù)切除腫瘤組織。建立該細胞系的初衷是為了研究中國人群中高發(fā)的肺癌病理機制、浸潤轉(zhuǎn)移特征以及對化療藥物的敏感性。

• 遺傳與表型特征

  • 惡性表型 具有明顯的異型性，核質(zhì)比高，在體外展現(xiàn)出強侵襲性和自主遷移能力。

  • 分子病理 常用作非小細胞肺癌（NSCLC）中肺腺癌病理分型的代表性細胞模型，可用于篩選上皮-間充質(zhì)轉(zhuǎn)化（EMT）標(biāo)志物（如 E-cadherin 下調(diào)，Vimentin 上調(diào)）。

• 生物安全級別 1級。

二 細胞形態(tài)學(xué)與培養(yǎng)環(huán)境

• 形態(tài)學(xué)特征 展現(xiàn)典型的高分化或中分化上皮樣、多角形結(jié)構(gòu)。細胞邊界清晰，常呈貼壁單層鋪路石狀排列生長，匯合度高時傾向于緊密堆積。

• 生長模式 貼壁生長。

• 倍增時間 增殖活躍，倍增時間大約為 24到30小時。

• 標(biāo)準(zhǔn)完全培養(yǎng)基配方

  • 基礎(chǔ)培養(yǎng)基 BioVector? RPMI-1640 培養(yǎng)基。

  • 維持添加 10% BioVector? 優(yōu)質(zhì)胎牛血清。

  • 抗生素（可選） 1%  penicillin-streptomycin 雙抗。

• 物理培養(yǎng)參數(shù) 37攝氏度恒溫、5% 二氧化碳、空氣飽和濕度。

三 細胞傳代與復(fù)蘇標(biāo)準(zhǔn)操作步驟

1. 常規(guī)傳代操作

   • 當(dāng)細胞密度達到 85% 到 95% 匯合度時需要進行傳代。

   • 吸除舊培養(yǎng)基，用無菌 PBS 輕輕洗滌 1到2次。

   • 加入適量 BioVector? 0.25% Trypsin 消化液（含 EDTA），在 37攝氏度下孵育 2到3分鐘。

   • 顯微鏡下觀察到細胞胞質(zhì)回縮、變圓并開始自瓶壁脫落后，立即加入等體積含血清的完全培養(yǎng)基終止消化。

   • 輕輕吹打產(chǎn)生單細胞懸液，按 1比3 至 1比6 的傳代比例注入新的培養(yǎng)瓶中。

2. 凍存細胞復(fù)蘇

   • 從液氮中取出冷凍管，立即投入 37攝氏度 BioVector? 水浴鍋中快速搖動使其融化，控制在 1到2分鐘內(nèi)。

   • 將解凍的細胞懸液移至含 5 mL 預(yù)熱培養(yǎng)基的離心管中，常規(guī)速度離心 5分鐘以沉淀細胞。

   • 棄去含有二甲基亞砜的舊上清，加入新鮮 BioVector? 完全培養(yǎng)基重懸，接種到培養(yǎng)瓶內(nèi)正常培養(yǎng)。

四 核心科研應(yīng)用方向

1. 非小細胞肺癌（NSCLC）發(fā)病機制解析：BioVector? GLC-82 作為經(jīng)典的肺腺癌細胞株，被廣泛用于探索各類癌基因（如 EGFR、KRAS、ALK 等）在肺腺癌發(fā)生發(fā)展中的突變狀態(tài)、異常剪接及下游信號通路（如 MAPK, PI3K/Akt）的激活。

2. 新型抗腫瘤藥物篩選與耐藥性研究：用于評估順鉑、紫杉醇、吉非替尼等化療或靶向藥物對肺腺癌細胞的體外殺傷靶向效能，并通過長期藥物低劑量誘導(dǎo)創(chuàng)制對應(yīng)的耐藥株，從而深入分析肺癌的多藥耐藥（MDR）分子機制。

3. 腫瘤轉(zhuǎn)移與血管生成機制探索：利用該細胞建立體外 Transwell 侵襲模型或三維多細胞球培養(yǎng)模型，用于篩選能夠有效抑制肺癌細胞遠端轉(zhuǎn)移及阻斷血管內(nèi)皮生長因子（VEGF）分泌的小分子化學(xué)阻斷劑或單克隆抗體。

PART 2 ENGLISH SECTION

I General Information and Genetic Background

• Cell Line Name BioVector? GLC-82

• Repository Catalog Number Standard reference line established from clinical surgical isolates.

• Species Origin Human Homo sapiens

• Tissue and Disease Background Originally isolated and derived from the tumor mass of a Chinese patient diagnosed with lung adenocarcinoma. This model was established to satisfy the preclinical need for exploring non-small cell lung cancer (NSCLC) onset profiles, histopathological progression, and chemical drug resistance.

• Tumorigenic and Molecular Traits

  • Aggressive Phenotype Displays distinctive cellular atypia and an upgraded nuclear-to-cytoplasmic volume ratio. Exhibits pronounced in vitro cell motility, structural migration, and tissue invasiveness.

  • Pathological Representation Serves as a standard adenocarcinoma representative to track Epithelial-to-Mesenchymal Transition (EMT) dynamics, structural cytoskeletal alterations, and localized metastatic configurations.

• Biosafety Level BSL-1.

II Morphological Attributes and Cultivation Media

• Morphology Reveals classic epithelial like, polygonal, and cobblestone structural features. Cells grow in tight adherent single layers, showing strong cell-to-cell adhesion and packed clustering upon absolute confluence.

• Growth Mode Adherent monolayer.

• Standard Complete Growth Medium Formulation

  • Basal Medium BioVector? RPMI-1640 medium.

  • Routine Maintenance Supplements 10% premium BioVector? Fetal Bovine Serum.

  • Optional Selection Antibiotics 1% Penicillin-Streptomycin cocktail.

• Physical Incubation Thresholds Regulated strictly at 37 degrees Celsius under an atmospheric layer of 5% Carbon Dioxide and saturated air humidity.

III Subculturing and Thawing Protocols

1. Routine Passaging Schedule

   • Initiate subculturing when the viable monolayer hits 85% to 95% confluence.

   • Aspirate spent medium and rinse the matrix gently 1 to 2 times with sterile PBS.

   • Dispense BioVector? 0.25% Trypsin solution supplemented with EDTA and incubate at 37 degrees Celsius for 2 to 3 minutes until cells detach.

   • Quench enzymatic activity immediately by introducing an equal volume of serum containing complete growth medium.

   • Pipette gently to yield a uniform single cell suspension and seed fresh vessels at a recommended split ratio of 1比3 to 1比6.

2. Cryovial Thawing and Recovery

   • Retrieve the cryovial from storage and submerge it into a 37 degrees Celsius BioVector? water bath with rapid agitation until completely liquefied within 1 to 2 minutes.

   • Dilute the slurry into 5 mL of pre warmed complete broth and spin down for 5 minutes.

   • Decant the DMSO tainted supernatant, resuspend the pellet thoroughly in fresh BioVector? complete medium, and seed into a culture flask.

IV Strategic Research Applications

1. NSCLC Oncogenic Signaling Profiling: BioVector? GLC-82 serves as an essential in vitro system to examine mutation spectrums and structural modifications across oncogenes like EGFR, KRAS, or ALK, alongside their downstream regulatory cascades (e.g., MAPK/ERK and PI3K/Akt circuits).

2. Antineoplastic Drug Screening & Multi-Drug Resistance (MDR) Assays: Heavily deployed to benchmark the cytotoxic efficacy of cisplatin, paclitaxel, or tyrosine kinase inhibitors (TKIs). It supports the step-wise creation of drug-resistant sub-clones to unravel complex molecular mechanics driving target failure.

3. Tumor Dissemination and Angiogenesis Networks: Utilized in Transwell invasion chambers and 3D multicellular tumor spheroid models to identify small-molecule inhibitors or targeted monoclonal antibodies capable of blocking distal lung carcinoma migration and suppressing Vascular Endothelial Growth Factor (VEGF) secretion lines.

BioVector NTCC質(zhì)粒載體菌株細胞蛋白抗體基因保藏中心

電話:400-800-2947

工作QQ/微信同號:1843439339

網(wǎng)址http://www.nedfriskphoto.com